Litigation Details for Sunovion Pharmaceuticals v. Dey Pharma (D. Del. 2006)

Sunovion Pharmaceuticals v. Dey Pharma (D. Del. 2006)

Docket		Date Filed	2006-02-22
Court	District Court, D. Delaware	Date Terminated	2012-05-25
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Both	Referred To
Patents	5,576,328
Link to Docket	External link to docket

Details for Sunovion Pharmaceuticals v. Dey Pharma (D. Del. 2006)

Date Filed	Document No.	Description	Snippet	Link To Document
2006-02-22				External link to document

Sunovion Pharmaceuticals v. Dey Pharma, 1:06-cv-00113: Litigation Summary and Patent Analysis

Last updated: August 10, 2026

Sunovion Pharmaceuticals v. Dey Pharma, L.P., No. 1:06-cv-00113, was an ANDA patent dispute in the U.S. District Court for the District of Delaware concerning Dey's proposed generic version of Xopenex, Sunovion's levalbuterol inhalation product. The case was filed in 2006 after Dey submitted a Paragraph IV certification challenging Sunovion patent protection. The action ended without a publicly reported trial judgment establishing invalidity or noninfringement. The parties resolved the dispute and the case was dismissed.

What drug and patents were involved in Sunovion v. Dey?

The litigation concerned levalbuterol hydrochloride, the active ingredient in Xopenex inhalation products.

Levalbuterol is the R-enantiomer of albuterol and is marketed for the treatment or prevention of bronchospasm associated with reversible obstructive airway disease. Xopenex was developed by Sepracor, which later became part of Sunovion Pharmaceuticals.

The case involved patent protection for levalbuterol and its pharmaceutical formulations. Public patent records associate the litigation with Sunovion's levalbuterol patent estate, including patents directed to the active enantiomer and inhalation formulations.

Item	Detail
Brand	Xopenex
Active ingredient	Levalbuterol hydrochloride
Dosage forms	Nebulized inhalation solution and inhalation aerosol products
Originator	Sepracor, later Sunovion Pharmaceuticals
Defendant	Dey Pharma, L.P.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:06-cv-00113
Filing year	2006
Litigation type	Hatch-Waxman ANDA litigation
Patent challenge	Paragraph IV certification
Outcome	Settlement and dismissal

The docket is sometimes confused with Sunovion's separate patent litigation over Lunesta, or eszopiclone. Civil Action No. 1:06-cv-00113 concerned Sunovion's respiratory franchise and Dey's proposed generic levalbuterol product, not the principal Lunesta patent cases.

When was Sunovion v. Dey filed and how did the case proceed?

Sunovion filed the action in 2006 after receiving notice that Dey had submitted an ANDA containing a Paragraph IV certification. Under the Hatch-Waxman framework, the filing of the patent infringement action triggered the statutory 30-month stay on FDA approval of Dey's ANDA, subject to earlier termination or court action. [1]

The principal procedural stages were:

Date or period	Event
2006	Sunovion filed the infringement complaint in Delaware
2006-2007	Dey answered and challenged the asserted patent rights
2007-2008	Claim construction, discovery and settlement activity proceeded
Settlement period	The parties resolved the patent dispute
Post-settlement	The action was dismissed rather than tried to judgment

The publicly available docket does not show a reported final merits decision determining that the asserted Sunovion patents were invalid. It also does not establish a Federal Circuit decision arising from this particular docket.

What was Dey's Paragraph IV strategy?

Dey's Paragraph IV certification represented that the proposed generic product would not infringe the listed Sunovion patents, or that the patents were invalid or unenforceable. A Paragraph IV filing permits an ANDA applicant to seek FDA approval before patent expiration, but it exposes the applicant to infringement litigation.

For Sunovion, the lawsuit preserved its ability to invoke the 30-month stay and negotiate a controlled generic-entry arrangement. For Dey, the filing created a path to earlier market entry and potential first-filer advantages, but also imposed litigation costs and the risk of an injunction.

The record is commercially significant because the case illustrates how a respiratory-product patent estate could delay or structure generic entry even after the active ingredient had been identified and approved.

What patents protected Xopenex and levalbuterol?

Sunovion's levalbuterol estate included patents directed to the optically pure active ingredient and pharmaceutical compositions. Public patent records identify U.S. Patent No. 5,362,755 and U.S. Patent No. 6,365,622 among the relevant levalbuterol patents.

U.S. Patent No. 5,362,755

U.S. Patent No. 5,362,755 covered optically pure beta-adrenergic agonists, including levalbuterol-related subject matter. Because it was an older patent, its term was materially shorter than later formulation patents. Its commercial value was concentrated in the period before later patents and regulatory exclusivities became the principal barriers to generic entry. [2]

U.S. Patent No. 6,365,622

U.S. Patent No. 6,365,622 covered pharmaceutical compositions involving optically pure beta-adrenergic agonists. The patent was more directly relevant to formulation and product protection than a broad active-ingredient patent.

The exact enforceability and expiry analysis depends on terminal disclaimers, patent-term adjustments, patent-term extensions and the specific claims listed in the FDA Orange Book. Patent expiry should therefore be assessed against the approved product's current Orange Book entries rather than against the issue date alone. [3]

What was the Orange Book status of Xopenex?

Xopenex products were subject to FDA-listed patent protections covering the active ingredient, formulations and delivery systems. The Orange Book identifies patents submitted by the NDA holder and provides the principal public reference for determining whether an ANDA applicant must make a Paragraph IV certification. [3]

The relevant regulatory structure was:

1. Sunovion held the approved NDA for Xopenex products.
2. Sunovion listed patent information with FDA.
3. Dey submitted an ANDA referencing the listed product.
4. Dey filed a Paragraph IV certification.
5. Sunovion sued within the statutory period.
6. FDA approval was subject to the Hatch-Waxman litigation stay and the later settlement terms.

Xopenex's regulatory exclusivity was separate from patent protection. FDA exclusivity periods can delay approval independently of patent expiry, but they do not extend the enforceable term of a patent. [1]

Did the case produce a patent-invalidity ruling?

No publicly reported decision from this docket established that Sunovion's levalbuterol patents were invalid. The case ended through settlement rather than a trial verdict or appellate ruling.

That distinction matters. A settlement does not validate the asserted patents in the legal sense, and it does not create binding precedent on claim construction, enablement, written description, obviousness or infringement. The settlement does show that the parties assigned commercial value to continued patent enforcement or to an agreed generic-entry framework.

The absence of a merits judgment leaves the following issues unresolved in this docket:

Legal issue	Public resolution in this case
Claim construction	No binding appellate resolution identified
Anticipation	No reported final merits ruling identified
Obviousness	No reported final merits ruling identified
Written description	No reported final merits ruling identified
Infringement	Resolved through settlement
Inequitable conduct	No reported final merits ruling identified
Patent enforceability	No reported final merits ruling identified

What were the settlement terms and generic-entry implications?

The settlement agreement was not publicly disclosed in full. The docket reflects resolution and dismissal, but the public record does not provide a complete commercial description of the parties' agreement.

The likely commercial elements of an ANDA settlement of this type include:

• A permitted generic-entry date.
• Restrictions on launch before patent expiry.
• Withdrawal or resolution of the Paragraph IV challenge.
• Allocation of first-filer or exclusivity rights.
• Possible supply, license or other commercial provisions.
• Dismissal of the infringement action.

No public record from this docket supports treating Dey as an unrestricted early entrant. The more conservative interpretation is that Sunovion preserved meaningful market protection while Dey obtained a contractual path to eventual entry.

Because the agreement was confidential, revenue forecasts should not assume that Dey could launch immediately after settlement. The relevant launch date would have depended on the settlement, FDA approval, regulatory exclusivity, manufacturing readiness and any remaining patent rights.

How strong was Sunovion's Xopenex patent estate?

Sunovion's estate had moderate-to-strong commercial characteristics but limited long-term durability.

Strengths

The estate combined multiple protection categories:

• Active-ingredient and stereochemical protection.
• Formulation protection.
• Product-specific Orange Book listings.
• FDA approval and established clinical use.
• A statutory litigation stay following the Paragraph IV filing.

The formulation claims were particularly important because they could remain commercially relevant after broad active-ingredient claims became vulnerable to expiry or invalidity challenges.

Weaknesses

The estate also had structural limitations:

• Older active-ingredient patents faced earlier expiry.
• Generic applicants could challenge claim scope and validity.
• Inhalation products require device, formulation and manufacturing equivalence, but those requirements do not eliminate ANDA competition.
• Settlement terms can reduce the practical value of remaining patent life.
• The product's market protection depended on several separate patents rather than one unlimited barrier.

The strongest enforcement position would have existed while a valid, Orange Book-listed patent covered the commercial product and before FDA approval of an ANDA became effective.

What generic-entry risks existed for Xopenex?

The case created several generic-entry scenarios.

Scenario 1: Delayed entry under settlement

Dey could remain excluded until a negotiated date. This was the most immediate commercial consequence of settlement.

Scenario 2: Entry after patent expiry

Dey or another ANDA applicant could enter after the relevant patents expired, subject to FDA approval and any remaining regulatory exclusivity.

Scenario 3: Later Paragraph IV litigation

Other generic applicants could file separate Paragraph IV certifications against later-listed patents or different dosage forms. A settlement with Dey would not necessarily bind unrelated ANDA applicants.

Scenario 4: Formulation or device design-around

A competitor could attempt to avoid infringement by using a different formulation, concentration, excipient system or delivery device, provided the ANDA product met FDA requirements.

Generic entry risk was therefore product-specific. Nebulized solution, metered-dose aerosol and other levalbuterol presentations could have different patent and regulatory profiles.

How did Sunovion v. Dey compare with other Xopenex competition?

Sunovion's main competitive exposure came from generic levalbuterol manufacturers and from branded short-acting beta-agonist products.

Competitor category	Competitive mechanism	Patent relevance
Generic levalbuterol	Lower-price substitution	Direct challenge to Xopenex patents
Generic albuterol	Therapeutic and price substitution	Indirect pressure on Xopenex
Other branded bronchodilators	Prescriber and formulary competition	Reduces brand retention
Authorized or licensed generic	Controlled price competition	Can preserve originator economics
Alternative delivery systems	Product differentiation	May avoid or narrow formulation claims

Xopenex's commercial exposure was greater for interchangeable inhalation solutions than for products with meaningful device or formulation differentiation. Once FDA approved a therapeutically equivalent generic, payer substitution could produce rapid price erosion.

What is the current litigation significance of the case?

The case is most useful as a historical example of Hatch-Waxman enforcement involving a respiratory product. It is not a leading precedent on Paragraph IV law because it did not generate a widely cited final appellate opinion.

For diligence purposes, the case establishes four points:

1. Dey actively challenged Sunovion's levalbuterol patent position.
2. Sunovion used litigation to preserve the value of its Xopenex franchise.
3. The parties resolved the dispute without a public invalidity judgment.
4. The commercial effect depended on confidential settlement terms and the remaining Orange Book patent term.

The case should be analyzed together with current Orange Book listings, FDA approval records, later generic approvals and any successor litigation involving levalbuterol products.

Key Takeaways

• Sunovion Pharmaceuticals v. Dey Pharma, No. 1:06-cv-00113, concerned generic levalbuterol, marketed by Sunovion as Xopenex.
• The action followed Dey's Paragraph IV certification and triggered Hatch-Waxman litigation protections.
• The relevant patent estate included levalbuterol active-ingredient and formulation patents, including U.S. Patent Nos. 5,362,755 and 6,365,622.
• The case ended through settlement and dismissal, not through a reported final judgment on patent validity or infringement.
• The settlement terms were not fully public, limiting precise analysis of Dey's authorized launch date.
• Formulation and product-specific patents were commercially important after older active-ingredient protection weakened.
• Generic-entry risk ultimately depended on patent expiry, FDA approval, regulatory exclusivity, product presentation and the terms of the settlement.

FAQs

Was Sunovion v. Dey a Lunesta patent case?

No. Civil Action No. 1:06-cv-00113 concerned levalbuterol and Xopenex. Sunovion's Lunesta litigation involved separate cases and different patents.

Did Dey launch a generic version of Xopenex immediately after settlement?

The public docket does not establish an unrestricted immediate launch. The settlement resolved the litigation, but the complete agreement and its launch provisions were not publicly disclosed.

Did the court hold Sunovion's levalbuterol patents valid?

No reported final merits decision from this docket established validity. The parties settled before a public trial judgment.

Were Xopenex patents listed in the FDA Orange Book?

Yes. Sunovion submitted patent information for approved Xopenex products, and those listings formed the basis for the Paragraph IV litigation framework.

Could another generic manufacturer challenge Xopenex after Dey settled?

Yes. A separate ANDA applicant could file its own certification and challenge listed patents, subject to the Hatch-Waxman framework, FDA requirements and any applicable exclusivity period.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services.

2. United States Patent and Trademark Office. (1994). U.S. Patent No. 5,362,755: Optically pure beta-adrenergic agonists. U.S. Department of Commerce.

3. United States Patent and Trademark Office. (2002). U.S. Patent No. 6,365,622: Pharmaceutical compositions containing optically pure beta-adrenergic agonists. U.S. Department of Commerce.

4. U.S. District Court for the District of Delaware. (2006). Sunovion Pharmaceuticals, Inc. v. Dey Pharma, L.P., No. 1:06-cv-00113. Civil docket.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.